Structural and functional brain changes in perimenopausal women who are susceptible to migraine: a study protocol of multi-modal MRI trial

Bo Hu†, Xu Wang‡, Jie-bing He, Yu-jie Dai, Jin Zhang, Ying Yu, Qian Sun, Lin-Feng Yan, Yu-Chuan Hu, Hai-Yan Nan, Yang Yang, Alan D. Kaye, Guang-Bin Cui* and Wen Wang*

Abstract

Background: As a common clinical symptom that often bothers midlife females, migraine is closely associated with perimenopause. Previous studies suggest that one of the most prominent triggers is the sudden decline of estrogen during perimenopausal period. Hormone replacement therapy (HRT) is widely used to prevent this suffering in perimenopausal women, but effective diagnostic system is lacked for quantifying the severity of the disease. To avoid the abuse and overuse of HRT, we propose to conduct a diagnostic trial using multimodal MRI techniques to quantify the severity of these perimenopausal migraineurs who are susceptible to the decline of estrogen.

Methods: Perimenopausal women suffering from migraine will be recruited from the pain clinic of our hospital. Perimenopausal women not suffering from any kind of headache will be recruited from the local community. Clinical assessment and multi-modal MR imaging examination will be conducted. A follow up will be conducted once half year within 3 years. Pain behavior, neuropsychology scores, fMRI analysis combined with suitable statistical software will be used to reveal the potential association between these above traits and the susceptibility of migraine.

Discussion: Multi-modal imaging features of both healthy controls and perimenopausal women who are susceptible to estrogen decline will be acquired. Imaging features will include volumetric characteristics, white matter integrity, functional characteristics, topological properties, and perfusion properties. Clinical information, such as basic information, blood estrogen level, information of migraine, and a bunch of neurological scale will also be used for statistic assessment. This clinical trial would help to build an effective screen system for quantifying the severity of illness of those susceptible women during the perimenopausal period.

Trial registration: This study has already been registered at Clinical Trials.gov (ID: NCT02820974). Registration date: September 28th, 2014.

Keywords: Perimenopausal, Migraine, Multi-modal, Voxel-based morphology (VBM), Functional connectivity (FC), Diffusional kurtosis imaging (DKI), Artery spin labeling (ASL)
Background
As a common headache disorder, migraine is characterized by recurrent headache attacks accompanied with symptoms including nausea and vomiting [1]. According to the World Health Organization (WHO), migraine is considered as one of the most disabling and burdensome diseases [2, 3]. In general, adult females experience migraine attacks twice more than males, and although men and women reported similar headache severity and frequency, women reported more migraine related symptoms [4, 5].

This gender difference is mainly caused by the difference in sex hormone. Estrogen quantities are relatively stable in men and undergo a much more gradual decline with age as compared with women [6]. For example, previous studies revealed that migraine is closely linked to the menopausal period of women, and one of the most prominent triggers is the sudden decline of estrogen [7–9]. Estrogen can bind to its receptors of nucleus or cytoplasm in the brain, and then exert its function of pain transmission by gene transcription and protein synthesis [10]. However, this procedure would be disturbed by the sudden drop of estrogen in perimenopausal period, which would furtherly result in the susceptibility to migraine [6].

Since the decline of estrogen begins in perimenopausal period, giving hormone replacement therapy (HRT) in this period is considered as an effective method to treat migraine [11, 12]. To avoid the abuse and overuse of HRT which could cause some severe unpleasant complications, those women should be given the lowest effective dose of medication [13, 14]. However, headache is a subjective feeling, and effective diagnostic system is still lacked for quantifying the degree of migraine, which could result in the abuse and overuse of HRT in treating this disease.

In the past two decades, functional magnetic resonance imaging (fMRI) technique has become an indispensable tool in migraine research and has greatly contributed to our understanding of migraine pathophysiology [15–17]. It could show anatomic and functional cerebral transformations associated with the clinical evolution and could be applied to most individuals without adverse effects. Maleki et al. found that female migraineurs have thicker posterior insula and precuneus cortices as compared with both male migraineurs and healthy controls of both sexes [18]. Compared to healthy controls, Kim and colleagues revealed a reduction of gray matter (GM) density in migraineurs, including insula, motor/premotor, prefrontal, cingulate, posterior parietal, and orbitofrontal cortex [19]. Huang et al. found reduced fractional anisotropy (FA) in the right frontal of migraine patients by using a tract-based spatial statistics (TBSS) method, which means the microstructure of white matter (WM) in that region is impaired [20]. Liu et al. found that the resting-state functional connectivity (FC) was disrupted in patients with long-term migraine through the method of graph theory [21]. However, these researches are all focused on both male and female patients at all ages, which contributes little to quantify the degree of migraine in perimenopausal women. According to our knowledge, no previous studies had researched the imaging abnormality of perimenopausal women who are susceptible to the decline of estrogen. Since estrogen plays a pivotal role in pain transmission in our brain [10], we thus raised the current hypothesis that brain structure and function of these women who are susceptible to estrogen drop exhibit unique characteristic changes in multi-modal images.

Consequently, we would like to conduct a prospective clinical trial to investigate the imaging abnormalities in these susceptible perimenopausal women. At the beginning, perimenopausal women around who had migraine will be recruited from the pain clinic of our hospital. Perimenopausal women around who did not have migraine will be recruited as healthy controls (HC) from the local community. Then, these subjects will undergo a series of multi-modal MRI brain scans and neuropsychology scales to assess the mental and physical state of these subjects. Multi-modal MR images of these two groups of subjects will be compared to find significant features as objective biomarkers.

Methods
The flowchart of the current trial is described in Fig. 1.

Subject
All subjects will be provided informed, written consents after the study procedure has been fully explained in detail. Females who match the following criteria would be included in the migraine group: (1) age ranges from 40 to 55 years old; (2) irregular menstrual cycle; (3) suffered from migraine; (4) normal neurological examination. Females who match the following criteria would be included in the HC group: (1) age ranges from 40 to 55 years old; (2) irregular menstrual cycle; (3) not suffered from any kinds of headache; (4) normal neurological examination. Exclusion criteria will be as follows: (1) severe psychiatric disorders, such as dementia, episode, epilepsy, major depression; (2) significant neurological illness, such as significant head trauma, tumor, meningitis or central nervous system (CNS) inflammatory lesions and vascular complications clues; (3) any MRI contraindications; (4) alcohol, nicotine or drug abuse.

Sample size have been estimated by referring to other studies [22, 23]. A sample size of 40 patients per group will be suitable for a power of 0.8 and an alpha significance level of 0.05 (two-side). Considering the drop-out
Demographic and clinical features of all subjects will be collected and recorded, such as age, education level, body mass index (BMI), occupation and menstrual cycle. All participants will receive the following battery of neuropsychological tests: Montreal Cognitive Assessment (MoCA) and Mini-mental State Examination (MMSE) will be used to assess the mental state of subjects. The Short Form health survey (SF-36) will be applied to evaluate the quality of life, and Self-rating Depression Scale (SDS) and Self-rating Anxiety Scale (SAS) will be performed to measure the severity of self-reported depression and anxiety. Migraine will be diagnosed according to the International Headache Society (IHS) criteria of the International Classification of Headache Disorders (ICHD-3 beta version) [1]. The following data will be collected from migraine participants: (1) type of migraine (migraine with aura, migraine without aura, etc.), (2) frequency of migraine attacks, (3) duration of migraine attacks, (4) headache location (unilateral or bilateral), (5) Migraine Disability Assessment Scale (MIDAS) score (the score is divided into 4 grades, higher grade means more severe disability). Blood samples were drawn at the screening centers and processed within 2 h according to a standardized protocol to assess the hormone level [24].

Follow up
A follow up will be conducted within three years after individual’s first visit. Individuals will come back to the medical center once half year for countercheck, and all the protocols and evaluations will be the same as that they get at the first time. In addition, medication type and dose will also be recorded.

Multi-modal MRI examination
Multi-modal imaging examination will be performed with a 3.0-T MRI system (MR750; GE Healthcare, Milwaukee, WI, USA) using an 8-channel head coil array with foam padding to restrict head motion. Multi-modal imaging examination will be performed with a 3.0-T MRI system (MR750; GE Healthcare, Milwaukee, WI, USA) using an 8-channel head coil array with foam padding to restrict head motion. Multi-modal imaging examination will be performed with a 3.0-T MRI system (MR750; GE Healthcare, Milwaukee, WI, USA) using an 8-channel head coil array with foam padding to restrict head motion.
scans including high-resolution three-dimensional brain volume T1-weighted imaging (T1WI), diffusion kurtosis imaging (DKI), resting-state blood oxygenation level-dependent (RS-BOLD) imaging and three-dimensional pseudo-continuous arterial spin labeling (3D-pCASL) imaging will be conducted to detect microstructural and functional properties. All the sequences we mentioned will use the isotropic spatial resolution.

**High-resolution T1WI**
Sagittal three-dimensional brain volume (3D-BRAVO) sequence will be used for the acquisition of high-resolution T1-weighted images, according to the following parameters: echo time (TE) = 3.2 ms, repetition time (TR) = 8.2 ms, TI = 450 ms, flip angle (FA) = 12°, field of view (FOV) = 256 × 256 mm², matrix = 256 × 192, slice thickness = 1.0 mm, slice number = 166. The whole procedure will cost 4 min 43 s.

**DKI**
DKI datasets will be collected using a double-spin-echo diffusion tensor echo planar imaging (SE-SS-DT-EPI) sequence with a clinically oriented protocol. The acquisition parameters are as follows: six b-values of 0, 500, 1000, 1500, 2000, and 2500 s/mm², 10 b₀ images, 30 diffusion gradient directions, TR = 6500 ms, TE = 108 ms, FOV = 256 × 256 mm², matrix = 128 × 128, slice thickness = 3 mm, FA = 90°, slice number = 50, voxel size = 2 mm × 2 mm × 5 mm. The acquisition time for this protocol will be 6 min.

**RS-bold**
RS-BOLD images will be collected using a gradient-recalled echo-planar imaging (GRE-EPI) sequence with the following parameters: TR = 2000 ms, TE = 40 ms, FA = 90°, slice number = 36, inter slice gaps = 0 mm, FOV = 240 × 240 mm², matrix = 64 × 64, slice thickness = 3 mm, in-plane spatial resolution = 3 × 3 mm². Participants will be reminded to lie quietly in the scanner with their eyes closed and thinking nothing during data acquisition. The whole procedure will cost 6 min 10 s.

**3D-pCASL**
Resting-state perfusion imaging was performed using pCASL sequence with a 3D fast spin-echo acquisition and background suppression: TR = 5046, 11.1 ms, FOV = 128 × 128 mm², matrix = 128 × 128 mm², slice thickness = 3 mm, FA = 111°, number of excitation = 3, no gap; 40 axial slices; number of excitation = 3. The whole procedure will cost 4 min 53 s.

**Imaging data processing**

**High-resolution T1WI data**
All T1 imaging data will be processed and examined for voxel-based morphological (VBM) analyses using the VBM8 toolbox (http://dbm.neuro.uni-jena.de/vbm/) in Statistical Parametric Mapping (SPM) (SPM8, Wellcome Department of Imaging Neuroscience Group, London, UK; http://www.fil.ion.ucl.ac.uk/spm) running in MATLAB 2014a platform. We will perform an optimized VBM protocol in which a brain-tissue-only template will be used other than a whole-brain template. Brain Extraction Tool (integrated in MRIcro; http://www.mricro.com) was used to remove non-brain region images [25]. After removal of nonbrain regions, images will be segmented into GM, white matter (WM), and cerebrospinal fluid (CSF) by using the Diffeomorphic Anatomical Registration Through Exponentiated Lie algebra (DARTEL) algorithm [26]. Afterward, the normalized images would be averaged by using SPM mean function. To create the final template, all average images would be smoothed using an isotropic Gaussian kernel with a full width at half maximum (FWHM) of 8 mm.

**DKI data**
All DKI images will be processed using a combination of FMRIB’s Software Library (FSL) [27] and in-house image processing tools developed in MATLAB. The diffusion dataset will be modulated to get potential 3D head motion and eddy current distortion using FSL eddy correct. The toolbox implement in MTALAB will be applied to deal with diffusional kurtosis tensors. Region of interest (ROI) of headache will be drawn by hand. DKI parameters of migraine pain-ROIs, such as mean kurtosis (MK), mean diffusivity (MD) and fractional anisotropy (FA), will be measured. All feature maps will be spatially normalized to the standard MNI space by using the transformation fields derived from tissue segmentation of structural images and resampled to 3 mm isotropic voxels.

**BOLD data**
RS-BOLD data will be preprocessed in the toolbox of MATLAB (Data Processing Assistant for Resting-State fMRI, DPARSF; http://www.restfmri.net/forum/DPARSF). SPM8, RS-fMRI data analysis toolkit (REST1.6; http://www.restfmri.net) and graph-theoretical network analysis (GRATNA; https://www.nitrc.org/projects/gretna) will also be selected to deal with the images. The first 10 time points will be discarded to ensure stable magnetization and allow the participants to adapt to the EPI scanning environment. After that, slice timing and head motion will be conducted, and scans with head motion of translation > 3.0 mm or rotation > 3° will be excluded. The functional images will then be spatially normalized to Montreal.
Neurological Institute (MNI) space using the transformation fields derived from tissue segmentation of individual structural images and resampled to $3 \times 3 \times 3 \text{ mm}^3$. The resulting images will be smoothed with 8 mm FWHM isotropic Gaussian kernel. Linear trends will be removed from the image time series, and data will be band-pass filtered at 0.01–0.08 Hz. Finally, nuisance signals such as 24-parameter head motion profiles, white matter, and cerebrospinal fluid signals will be regressed out from each voxel’s time series to exclude non-neuronal sources [28]. Amplitude of low frequency fluctuation (ALFF), regional homogeneity (ReHo) and functional connectivity (FC) values will be estimated in the DPARSFA software that is developed to extract abnormal regions between two groups. Small-world properties and network efficiency will be calculated in the GREtnA software to compare the topological characteristics between two groups.

**3D-pCASL data**

For the ASL fMRI data, corresponding CBF images were obtained using an automated image postprocessing tool embedded in the GE healthcare MR-750 system. Subsequently, the CBF images will be spatially normalized to the standard MNI space by using the transformation fields derived from tissue segmentation of structural images and resampled to 3 mm isotropic voxels. The resulting images will be transformed to z scores using Fisher’s transformation approach and then will be smoothed with 8 mm FWHM isotropic Gaussian kernel.

**Statistical analysis**

Statistical Package for the Social Sciences (SPSS) 18.0 (SPSS, Chicago, IL, USA) will be used to analyze the socio-demographic and clinical data. SPM8 and REST 1.8 will be used to analyze the imaging data. All statistical tests were conducted with a significance level of 5%.

**Socio-demographic and clinical data**

We will use 2-sample Student-t test for discrete quantitative data (age, body mass index, educational level, migraine history, frequency of migraine attacks, duration of migraine attacks, SAS score, SDS score, MMSE score, MoCA score and MIDAS scores), and the chi-square ($\chi^2$) test for nominal qualitative data (gender, type and location of migraine).

**Structural parameters**

Both voxel-based and ROI-based 2-sample Student-t test will be applied to compare global gray matter (GMV) MK, MD and FA between susceptible group and healthy control group with age, sex, education and BMI as covariance. Moreover, non-parametric Spearman correlation will be performed to delineate a possible relationship between local morphologic alterations and clinical data as well as diffusional alterations and clinical data. Significance threshold, which is corrected for comparison using Family Wise Error (FWE) method, will be set at $P < 0.05$. For each design matrix, significant effects both in the negative and positive directions are considered.

**Functional and perfusion parameters**

Both voxel-based and ROI-based 2-sample Student-t test will be applied to compare global ReHo, ALFF/fALFF, CBF between susceptible group and healthy control group with age, sex, education and BMI as covariance. The reference time series for headache-related seed regions will be acquired by averaging the time series for all voxels within them. Correlations of this time-series will be calculated to measure FCs among these regions in each participant. To evaluate group differences in the resting-state topological properties, nonparametric permutation tests were applied [29]. Initially, we will calculate the between-group differences of the mean values for each topological property. Next, an empirical distribution of the difference will be obtained by randomly reallocating every property value into two groups and recomputing the mean differences between the two randomized groups (5,000 permutations) to test the null hypothesis that the observed group differences only occurred by chance. The 95th percentile points of each distribution will be used as critical values for a two-tailed test to determine whether the observed group differences could occur by chance. Non-parametric Spearman correlation will also be performed to delineate a possible relationship between functional alterations and clinical data as well as perfusion alterations and clinical data. Significance threshold will be set at $P < 0.05$ (FWE corrected).

**Correlation analysis**

Linear regression analysis will be performed across the migraine groups to assess relationships between imaging properties and cognitive testing scores and clinical information. When the most sensitive parameters are found, a receiver operating characteristic (ROC) curve will be plotted to testify the sensitivity and specificity of the certain parameter for quantifying the degree of migraine and screening the accompanied cognitive decline.

**Outcomes measure**

**Primary outcomes measure**

White matter integrity (e.g. MD, MK and FA changes),

**Secondary outcomes measure**

Headache level (1–10, VAS), volumetric characteristics (e.g. GMV atrophy), functional characteristics (e.g. ReHo, ALFF/fALFF and FC and abnormalities), topological
properties (e.g. small-world properties and network efficiency) and perfusion properties (e.g. CBF changes).

Discussion
Multi-modal imaging features of perimenopausal women who are susceptible to estrogen decline will be acquired. Imaging sequences will include 3D-BRAVO, DKI, RS-BOLD and 3D-pCASL. Imaging features for assessment will include volumetric characteristics, white matter integrity, functional characteristics, topological properties and perfusion properties. Clinical information, such as information of migraine, headache level, MIDAS score, SAS, SDS, MMSE, MoCA and SF-36 will also be acquired for assessment.

The structural imaging could reflect the long-term impact of migraine on the brain structure, including GM volume and WM integrity. VBM has been pervasively used to investigate structural changes in migraine in the last decade. Some of them observed significant GM abnormalities in several brain regions of migraine patients [30–32], including right superior temporal gyrus, right inferior frontal gyrus and left precentral gyrus etc., but the result in other studies were not significant [33–35]. Two recent meta-analysis considered that migraine could cause GMV changes, and these changes were related to gender [36]. The integrity of WM is usually measured by calculating several parameters of its diffusional ability, such as MD, MK and FA. Several previous studies had compared these parameters between migraine patients and healthy controls, and they found significant increases or decreases in brain regions like thalami, corpus callosum and internal capsule [37–40]. Previous studies had also investigated the difference of WM integrity between migraine patients with and without aura and between ictal and interictal period [37, 41]. In addition, imaging researches about WM integrity in children or adolescent who have migraine had also been conducted [42, 43]. In the current study, we hope that the long-term impact of the susceptibility of estrogen drop on brain structure could also be reflected in structural imaging.

The functional imaging could reflect the impact of migraine on the brain activity, including neural activity and perfusion condition. RS-BOLD signal had attracted considerable attention in migraine patient to examine potential alterations of brain induced by recurrent migraine attacks. In migraine patients, previous studies have detected various alterations regarding functional connectivity in pain related regions including the periaqueductal gray area (an important region involved in nociceptive processing) [44], as well as insular which is stronger functionally coupled to the dorsal caudal pons and periaqueductal gray area than healthy controls [45]. Other recent studies have reported changed ReHo, ALFF/fALFF or FC in the executive control network [46, 47], and the default mode network [35]. In addition, the functional topologic properties of migraineurs were also observed in precentral gyrus, anterior cingulate gyrus, thalamus and etc. [21, 48]. Previous researches had identified CBF abnormalities as an imaging biomarker in migraineurs, but these CBF studies were all based on single-photon emission computed tomography (SPECT), which is invasive and difficult to generalize in clinical trial [49, 50]. Recently, ASL is an emerging MRI sequence that can be easily performed without contrast injection or any side effects. Some recent studies stressed the significant abnormalities in somatosensory cortex or other brain regions of migraineurs [51, 52], while one study declared that they didn’t see and significant changes [53]. We hope that the impact of the susceptibility of estrogen drop on brain activity could also be reflected in functional imaging.

Trial status
This is the first version of the study protocol, and the recruitment had begun in July 2016, and it will be completed in around 2020.

Abbreviations
3D-pCASL: three-dimensional pseudo-Continuous Arterial Spin Labeling; ALFF: Amplitude of Low Frequency Fluctuation; DKI: Diffusion Kurtosis Imaging; FA: Fractional Anisotropy; FMRI: Functional Magnetic Resonance Imaging; GM: Gray Matter; HRT: Hormone Replacement Therapy; MD: Mean Diffusivity; MK: Mean Kurtosis; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; PB: Partial volume effect; ReHo: Regional Homogeneity; ROI: Region Of Interest; RS-BOLD: Resting-State Blood Oxygenation Level-Dependent; SAS: Self-rating Anxiety Scale; SDS: Self-rating Depression Scale; SF-36: Short Form health survey; T1WI: T1-Weighted Imaging; TBSS: Tract-Based Spatial Statistics; WM: White Matter

Acknowledgements
We would like to thank Shang Lei for the insightful discussions on the sample size calculation and Liu Xu-Feng for the help with neuropsychological assessments selection.

Funding
This study is financially supported with the Natural Science Foundation of China (No. 81571656 to Dr. Wen Wang) and Key Project for Science Research and Development of Shaanxi Province (No. 2017SF-012 to Dr. Hai-Yan Nan) but not commercial organization. The funding source has estimated the feasibility of the study, but has no role in the collection, analysis, or interpretation of the data or in the decision to submit the manuscript for publication.

Availability of data and materials
The datasets supporting the conclusions of this article will available after we update the information in the ClinicalTrials.gov (NCT02820974).

Authors’ contributions
All authors contributed to this project. BH and XW contributed equally to this project in preparing the protocol, informed consent and trial registration. JBH and YD drafted the manuscript. JZ, YY, QS, LFY, HYN, YCH, and ADK made critical revision of the manuscript for important intellectual content. CGB and WW are corresponded equally to this study. All authors read and approved the final manuscript.
Ethics approval and consent to participate

The experiment conformed to the principles of the Declaration of Helsinki and was approved by the ethics committee of the second affiliated hospital (Tangdu Hospital) of Fourth Military Medical University (TDLL-2015133). All subjects will be provided informed, written consents after the study procedure has been fully explained in detail.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Radiology & Functional and Molecular Imaging Key Lab of Shaanxi Province, Tangdu Hospital, Fourth Military Medical University (Air Force Medical University), 569 Xiuxi Road, Xi’an 710038, Shaanxi, China.
2Student Brigade, Fourth Military Medical University (Air Force Medical University), 169 West Changle Road, Xi’an 710032, Shaanxi Province, China.
3Department of Clinical Nutrition, Xijing Hospital, The Fourth Military Medical University, Xi’an, China.
4Departments of Anesthesiology and Pharmacology, Louisiana State University School of Medicine, New Orleans, Louisiana, USA.

Received: 1 August 2018 Accepted: 29 August 2018

Published online: 06 September 2018

References

1. Headache Classification Committee of the International Headache S: the international classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013; 33(9):629–808.
2. Leonard M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO’s classification of functioning, disability and health (ICF). J Headache Pain. 2005;6(6):429–40.
3. Buse DC, Lipton RB. Global perspectives on the burden of episodic and chronic migraine. Cephalalgia. 2015;35(11):885–90.
4. Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015;55(1):21–34.
5. Buse DC, Loder EW, Gorman JA, Stewart WF, Reed ML, Fanning KM, Serrano D, Lipton RB. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American migraine prevalence and prevention (AMPP) study. Headache. 2013;53(8):1278–99.
6. Chai NC, Peterlin BL, Calhoun AH. Migraine and estrogen. Curr Opin Neurol. 2014;27(3):315–24.
7. MacGregor EA. Migraine, the menopause and hormone replacement therapy: a clinical review. J Fam Plann Reprod Health Care. 2007;33(4):245–9.
8. Martin VT. Migraine and the menopausal transition. Neurol Sci. 2014;35(suppl 1):165–9.
9. Martin VT, Pavlovic JS, Fanning KM, Buse DC, Reed ML, Lipton RB. Perimenopause and menopause are associated with high frequency headache in women with migraine: results of the American migraine prevalence and prevention study (AMPP) study. Headache. 2013;53(8):1278–99.
10. Chai NC, Peterlin BL, Calhoun AH. Migraine and estrogen. Curr Opin Neurol. 2014;27(3):315–24.
11. MacGregor EA. Migraine, the menopause and hormone replacement therapy: a clinical review. J Fam Plann Reprod Health Care. 2007;33(4):245–9.
12. Martin VT. Migraine and the menopausal transition. Neurol Sci. 2014;35(suppl 1):165–9.
13. Martin VT, Pavlovic JS, Fanning KM, Buse DC, Reed ML, Lipton RB. Perimenopause and menopause are associated with high frequency headache in women with migraine: results of the American migraine prevalence and prevention study. Headache. 2016;56(2):292–305.
14. Amanodison A, Blomqvist S. Estrogenic influences in pain processing. Headache. 2015;55(1):21–34.
15. Chai NC, Peterlin BL, Calhoun AH. Migraine and estrogen. Curr Opin Neurol. 2014;27(3):315–24.
16. Chen Z, Chen X, Liu M, Liu S, Shu S, Ma L, Yu S. Altered functional connectivity of the marginal division in migraine: a resting-state fMRI study. J Headache Pain. 2016;17(1):89.
17. Huang J, Deliano M, Cao Y. Visual cortical inhibitory function in migraine is not generally impaired: evidence from a combined psychophysical test with an fMRI study. Cephalalgia. 2006;26(2):554–60.
18. Maleki N, Linnman C, Brawn J, Bustin R, Becerra L, Borsook D. Her versus his migraine: multiple sex differences in brain function and structure. Brain. 2012;135(Pt 8):2546–59.
19. Kim JH, Suh SJ, Seol HY, Oh K, Seo WK, Yu SW, Park KW, Koh SB. Regional grey matter changes in patients with migraine: a voxel-based morphometry study. Cephalalgia. 2008;28(6):598–604.
20. Huang Q, Xu X, He Y, Wei X, Ma M, Liao Y, Qin C, Wu Y. Structural differences in interictal migraine attack after epilepsy: a diffusion tensor imaging analysis. Epilepsy Behav. 2017;77:8–12.
21. Liu J, Zhao L, Lei F, Zhang Y, Yuan K, Gong Q, Liang F, Tian J. Disrupted resting-state functional connectivity and its changing trend in migraine suffers. Hum Brain Mapp. 2015;36(5):1892–907.
22. Aloi CP, Detre JA, Gobay X, Gunther M, Hendrickse J, Hernandez-Garcia L, Lu H, MacIntosh BJ, Park LM, Smits M, et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med. 2015;73(1):102–16.
23. Ruinek H, Ha J, You PL, Storey P, Tarsi A, Tsai WH, Frosch O, Azova S, Conivit A. Cerebral perfusion in insulin resistance and type 2 diabetes. J Cereb Blood Flow Metab. 2015;35(5):395–102.
24. Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P, Reding D, Gelmann EP, Rothman N, Pfeffer RM, et al. Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res. 2005;592(1–2):147–54.
25. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17(3):143–50.
26. Ashburner J. A fast deformorphic image registration algorithm. Neuroimage. 2007;38(1):95.
27. Ashburner J. Neuroimage. Advances in functional and structural MR image analysis and implementation as FSL Neuroimage. 2004;23(suppl 1):3208–18.
28. Friston KJ, Williams S, Howard R, Frackowiak RS, Turner R. Movement-related effects in fMRI time-series. Magn Reson Med. 1996;35(3):346–55.
29. Bullmore ET, Suckling J, Overmeyer S, Rabe-Hesketh S, Taylor E, Brammer MJ. Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Trans Med Imaging. 2002;18(1):32–42.
30. Valfie WR, Rainiero I, Bergui M, Pinelli L. Voxel-based morphometry reveals gray matter abnormalities in migraine. Headache the J Head & Face Pain. 2010;48(S1):109–17.
31. Jin C, Yuan K, Zhao L, Zhao L, Yu D, Deneen K, Zhang M, Qin W, Sun W, Tian J. Structural and functional abnormalities in migraine patients without aura. NMR Biomed. 2013;26(1):58–64.
32. Obermann M, Wrathmann S, Steinberg BS, Theysohn N, Diener HC, Naegel S. Central vestibular system modulation in vestibular migraine. Cephalalgia. 2014;34(13):1053–61.
33. Schmidtwillke T, Gainsbaur S, Neurten T, Bobdahn U, May A. Subtle grey matter changes between migraine patients and healthy controls. Cephalalgia. 2008;28(1):1–4.
34. Russo A, Testore A, Giordano A, Corbo D, Marcuccio L, De SM, Salemi F, Contini R, Esposito F, Tedeschi G. Executive resting-state network connectivity in migraine without aura. Cephalalgia. 2012;32(14):1041.
35. Testore A, Russo A, Giordano A, Conti F, Corbo D, Stefano MD, Cirillo S, Cirillo M, Esposito F, Tedeschi G. Disrupted default mode network connectivity in migraine without aura. J Headache & Pain. 2013;14(1):1–7.
36. Dai Z, Zhong J, Xiao P, Zhu Y, Chen F, Pan P, Shi H. Gray matter correlates of migraine and gender effect: a meta-analysis of voxel-based morphometry studies. Neuroscience. 2015;29288–96.
37. Coppola G, Tinelli L, Lepre P, Di Li CC, Da GL, Serra M, Pauni F, Fierrmonte G, Bianco F. Dynamic changes in thalamic microstructure of migraine without aura patients: a diffusion tensor magnetic resonance imaging study. Eur J Neurol. 2014;21(2):827–e213.
38. Kara B, Kiyat AA, Onat L, Ulusoy L, Mutlu A, Sinavaci M. DTI findings during spontaneous migraine attacks. Clin Neuroradiol. 2013;23(1):31.
39. Yu D, Yuan K, Zhao L, Dong M, Liu P, Yang X, Liu J, Sun J, Zhou G, Xue T. White matter integrity affected by depressive symptoms in migraine without aura: a tract-based spatial statistics study. NMR Biomed. 2013;26(9):1103–12.

40. Kai Y, Wei Q, Peng L, Ling Z, Yu D, Zhao L, Dong M, Liu J, Yang X, Deneen KMV. Reduced fractional anisotropy of Corpus callosum modulates inter-hemispheric resting state functional connectivity in migraine patients without Aura. PLoS One. 2012;7(9):e45476.

41. Rocca MA, Pagani E, Colombo B, Tortorella P, Falini A, Corni G, Filippi M. Selective diffusion changes of the visual pathways in patients with migraine: a 3-T tractography study. Cephalalgia. 2008;28(10):1061–8.

42. Eidtitz-Markus T, Zeharia A, Haimi-Cohen Y, Konen O. MRI white matter lesions in pediatric migraine. Cephalalgia. 2013;33(11):906–13.

43. Candee MS, McCandless RT, Moore KR, Arrington CB, Minich LL, Bale JF, Jr. White matter lesions in children and adolescents with migraine. Pediatr Neurol 2013, 49(6):393–396.

44. Mainiero C, Boshyan J, Hadjikhani N. Altered functional magnetic resonance imaging resting-state connectivity in periaqueductal gray networks in migraine. Ann Neurol. 2011;70(3):388–401.

45. Tso AR, Trujillo A, Guo CC, Goadsby PJ, Seeley WW. The anterior insula shows heightened interictal intrinsic connectivity in migraine without aura. Neurology. 2015;84(10):1043–50.

46. Tessitore A, Russo A, Conte F, Giordano A, De Stefano M, Lavorgna L, Corbo D, Caiazzo G, Esposito F, Tedeschi G. Abnormal connectivity within executive resting-state network in migraine with Aura. Headache. 2015;55(9):974–805.

47. Russo A, Marcelli V, Esposito F, Corvino V, Marcuccio L, Giannone A, Conforti R, Marciano E, Tedeschi G, Tessitore A. Abnormal thalamic function in patients with vestibular migraine. Neurology. 2014;82(23):2120–6.

48. Liu J, Zhao L, Li G, Xiong S, Nan J, Li J, Yuan K, von Deneen KM, Liang F, Qin W, et al. Hierarchical alteration of brain structural and functional networks in female migraine sufferers. PLoS One. 2012;7(12):e51250.

49. Nishiyama M, Matsuda H, Imabayashi E, Kaji I, Sato N. Comparison of SPM and NEUROSTAT in voxelwise statistical analysis of brain SPECT and MRI at the early stage of Alzheimer’s disease. Ann Nucl Med. 2008;22(10):921–7.

50. Ansar MA, Oskai Y, Kazui H, Oku N, Takazawa M, Kimura Y, Begum NN, Ikejiri Y, Takeda M, Hatazawa J. Effect of linearization correction on statistical parametric mapping (SPM): a 99mTc-HMPAO brain perfusion SPECT study in mild Alzheimer’s disease. Ann Nucl Med. 2006;20(8):511–7.

51. Youssef AM, Ludwick A, Wilcox SL, Lebel A, Peng K, Colon E, Daneyh A, Burstein R, Becerra D, Borsook D. In child and adult migraineurs the somatosensory cortex stands out... Again: an arterial spin labeling investigation. Hum Brain Mapp. 2017;38(8):4078–87.

52. Cadiot D, Longuay R, Bruneau B, Treguer C, Cansin-Yu A, Corouge I, Gones C, Proux M. Magnetic resonance imaging in children presenting migraine with aura: association of hyperperfusion detected by arterial spin labelling and vasoactivity on MR angiography findings. Cephalalgia. 2018;38(5):949–58.

53. Gil-Gouveia R, Pinto J, Figueiredo P, Vilela PF, Martins IP. An arterial spin labeling MRI perfusion study of migraine without Aura attacks. Front Neurol. 2017;9:280.